Literature DB >> 15781641

Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth.

Kelly L Covello1, M Celeste Simon, Brian Keith.   

Abstract

Hypoxia-inducible factors (HIF) are essential transcriptional regulators that mediate adaptation to hypoxic stress in rapidly growing tissues such as tumors. HIF activity is regulated by hypoxic stabilization of the related HIF-1alpha and HIF-2alpha subunits, which are frequently overexpressed in cancer cells. To assess the relative tumor-promoting functions of HIF-1alpha and HIF-2alpha directly, we replaced HIF-1alpha expression with HIF-2alpha by creating a novel "knock-in" allele at the Hif-1alpha locus through homologous recombination in primary murine embryonic stem cells. Compared with controls, s.c. teratomas derived from knock-in embryonic stem cells were larger and more proliferative, had increased microvessel density, and exhibited increased expression of vascular endothelial growth factor, transforming growth factor-alpha, and cyclin D1. These and other data indicate that HIF-2alpha promotes tumor growth more effectively than HIF-1alpha in multiple contexts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781641     DOI: 10.1158/0008-5472.CAN-04-3246

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia.

Authors:  Kyoung Eun Lee; Michelle Spata; Lauren J Bayne; Elizabeth L Buza; Amy C Durham; David Allman; Robert H Vonderheide; M Celeste Simon
Journal:  Cancer Discov       Date:  2015-12-29       Impact factor: 39.397

2.  Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo.

Authors:  William Y Kim; Michal Safran; Marshall R M Buckley; Benjamin L Ebert; Jonathan Glickman; Marcus Bosenberg; Meredith Regan; William G Kaelin
Journal:  EMBO J       Date:  2006-09-14       Impact factor: 11.598

3.  The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo.

Authors:  Qin Yan; Steven Bartz; Mao Mao; Lianjie Li; William G Kaelin
Journal:  Mol Cell Biol       Date:  2007-01-12       Impact factor: 4.272

4.  The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression.

Authors:  Kenneth K-W To; Olga A Sedelnikova; Melissa Samons; William M Bonner; L Eric Huang
Journal:  EMBO J       Date:  2006-10-05       Impact factor: 11.598

5.  von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis.

Authors:  Michele M Hickey; Jennifer C Lam; Natalie A Bezman; W Kimryn Rathmell; M Celeste Simon
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

6.  Heterozygosity for hypoxia inducible factor 1alpha decreases the incidence of thymic lymphomas in a p53 mutant mouse model.

Authors:  Jessica A Bertout; Shetal A Patel; Benjamin H Fryer; Amy C Durham; Kelly L Covello; Kenneth P Olive; Michael H Goldschmidt; M Celeste Simon
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

Review 7.  Hypoxic tumor microenvironment and cancer cell differentiation.

Authors:  Yuri Kim; Qun Lin; Peter M Glazer; Zhong Yun
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

8.  The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha.

Authors:  Cheng-Jun Hu; Aneesa Sataur; Liyi Wang; Hongqing Chen; M Celeste Simon
Journal:  Mol Biol Cell       Date:  2007-09-05       Impact factor: 4.138

9.  VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.

Authors:  C M Lee; M M Hickey; C A Sanford; C G McGuire; C L Cowey; M C Simon; W K Rathmell
Journal:  Oncogene       Date:  2009-03-02       Impact factor: 9.867

Review 10.  Hypoxia-inducible factors in stem cells and cancer.

Authors:  Jolly Mazumdar; Vijay Dondeti; M Celeste Simon
Journal:  J Cell Mol Med       Date:  2009-11-09       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.